According to related industries, Roche Korea has submitted an application for Polivy (Polatuzumab), an antibody-drug conjugate (ADC) that is used in combination with conventional BR therapy (Bendamustine+Rituximab) for the treatment of Diffuse Large B-Cell Lymphoma and DLBCL.
DLBCL, which accounts for the highest proportion of Non-Hodgkin lymphomas, is an aggressive lymphoma that requires immediate treatment due to its rapid disease progression. More than half of the patients have a good response rate to the extent of reaching remission, but 30-40% of patients do not respond to the standard therapy R-CHOP or experience recurrence after the first treatment.

Relapsed/refractory DLBCL has not been a